Three-year outcomes after revascularization with everolimus- and sirolimus-eluting stents from the SORT OUT IV trial

JACC: Cardiovascular Interventions

Volumn 7, Issue 8, 2014, Pages 840-848

  Jensen, Lisette Okkels ^a   Thayssen, Per ^a   Maeng, Michael ^b   Christiansen, Evald Høj ^b   Ravkilde, Jan ^c   Hansen, Knud Nørregaard ^a   Kaltoft, Anne ^b   Tilsted, Hans Henrik ^c   Madsen, Morten ^b   Lassen, Jens Flensted ^b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

drug eluting stent; percutaneous coronary intervention; very late definite stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; CARDIOVASCULAR AGENT; EVEROLIMUS;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; DEVICE SAFETY; DRUG ELUTING CORONARY STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; IMPLANTATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE COMPLICATION; MONOTHERAPY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STENT THROMBOSIS; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; EVEROLIMUS ELUTING CORONARY STENT; MIDDLE AGED; PATIENT SAFETY; RISK FACTOR; SIROLIMUS ELUTING CORONARY STENT; THERAPY EFFECT; ADVERSE EFFECTS; AGED; CLINICAL TRIAL; CORONARY THROMBOSIS; DEVICES; DRUG ELUTING STENT; MORTALITY; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROPORTIONAL HAZARDS MODEL; PROSTHESIS; REGISTER; SCANDINAVIA; TIME; TREATMENT OUTCOME;

AGED; CARDIOVASCULAR AGENTS; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; EVEROLIMUS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; REGISTRIES; RISK FACTORS; SCANDINAVIAN AND NORDIC COUNTRIES; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME;

EID: 84906791962     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2014.02.014     Document Type: Article

References (23)

1. M.C. Morice, P.W. Serruys, and J.E. Sousa et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization N Engl J Med 346 2002 1773 1780
2. J.W. Moses, M.B. Leon, and J.J. Popma et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery N Engl J Med 349 2003 1315 1323
3. G.W. Stone, S.G. Ellis, and D.A. Cox et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease N Engl J Med 350 2004 221 231
4. J. Daemen, P. Wenaweser, and K. Tsuchida et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study Lancet 369 2007 667 678
5. L.O. Jensen, H.H. Tilsted, and P. Thayssen et al. Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry EuroIntervention 5 2010 898 905
6. P.C. Smits, E. Kedhi, and K.J. Royaards et al. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTE stent in all-comers: a randomized open label trial) J Am Coll Cardiol 58 2011 11 18
7. G.W. Stone, A. Rizvi, and K. Sudhir et al. Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial J Am Coll Cardiol 58 2011 19 25
8. S. Silber, S. Windecker, P. Vranckx, and P.W. Serruys Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial Lancet 377 2011 1241 1247
9. M. Maeng, H.H. Tilsted, and L.O. Jensen et al. 3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents J Am Coll Cardiol Intv 5 2012 812 818
10. A.J. Kirtane, M.B. Leon, and M.W. Ball et al. The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent J Am Coll Cardiol Intv 6 2013 325 333
11. L.O. Jensen, P. Thayssen, and H.H. Tilsted et al. Rationale and design of a randomized clinical comparison of everolimus-eluting (Xience V/Promus) and sirolimus-eluting (cypher select+) coronary stents in unselected patients with coronary heart disease Cardiology 116 2010 73 78
12. L.O. Jensen, P. Thayssen, and H.S. Hansen et al. Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention. The SORT OUT IV Trial Circulation 125 2012 1246 1255
13. D.E. Cutlip, S. Windecker, and R. Mehran et al. Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
14. T.F. Andersen, M. Madsen, J. Jorgensen, L. Mellemkjoer, and J.H. Olsen The Danish National Hospital Register. A valuable source of data for modern health sciences Dan Med Bull 46 1999 263 268
15. M.E. Charlson, P. Pompei, K.L. Ales, and C.R. MacKenzie A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 1987 373 383
16. L.O. Jensen, M. Maeng, and A. Kaltoft et al. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions J Am Coll Cardiol 50 2007 463 470
17. L. Frank Epidemiology. When an entire country is a cohort Science 287 2000 2398 2399
18. T.A. Gooley, W. Leisenring, J. Crowley, and B.E. Storer Estimation of failure probabilities in the presence of competing risks: new representations of old estimators Stat Med 18 1999 695 706
19. G.G. Stefanini, B. Kalesan, and P.W. Serruys et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial Lancet 378 2011 1940 1948
20. P. Thayssen, L.O. Jensen, and J.F. Lassen et al. The risk and prognostic impact of definite stent thrombosis or in-stent restenosis after coronary stent implantation EuroIntervention 8 2012 591 598
21. R.A. Byrne, A. Kastrati, and S. Massberg et al. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial J Am Coll Cardiol 58 2011 1325 1331
22. L. Raber, P. Juni, and E. Nuesch et al. Long-term comparison of everolimus-eluting and sirolimus-eluting stents for coronary revascularization J Am Coll Cardiol 57 2011 2143 2151
23. T. Palmerini, G. Biondi-Zoccai, and R.D. Della et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis Lancet 379 2012 1393 1402